HC Wainwright Expects Stronger Earnings for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA) – HC Wainwright increased their Q1 2026 earnings per share estimates for Cabaletta Bio in a research note issued to investors on Wednesday, April 1st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their prior forecast of ($0.47). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.51) EPS, Q4 2027 earnings at ($0.37) EPS, FY2027 earnings at ($1.48) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($0.64) EPS.

CABA has been the subject of several other research reports. Guggenheim boosted their price objective on shares of Cabaletta Bio from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Wall Street Zen upgraded shares of Cabaletta Bio from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a report on Wednesday, January 21st. Finally, Morgan Stanley decreased their price objective on Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating for the company in a report on Tuesday, March 24th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Cabaletta Bio presently has an average rating of “Moderate Buy” and an average target price of $17.00.

Cabaletta Bio Stock Performance

NASDAQ:CABA opened at $2.96 on Friday. The company’s 50-day simple moving average is $2.93 and its 200-day simple moving average is $2.60. Cabaletta Bio has a fifty-two week low of $0.99 and a fifty-two week high of $3.78. The stock has a market capitalization of $329.51 million, a P/E ratio of -1.30 and a beta of 3.30.

Cabaletta Bio (NASDAQ:CABA) last announced its earnings results on Monday, March 30th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05.

Insider Transactions at Cabaletta Bio

In other news, Director Shawn Tomasello bought 22,725 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was purchased at an average price of $2.21 per share, with a total value of $50,222.25. Following the completion of the acquisition, the director directly owned 22,725 shares of the company’s stock, valued at $50,222.25. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steve Gavel purchased 22,170 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was acquired at an average price of $2.27 per share, for a total transaction of $50,325.90. Following the acquisition, the insider owned 22,170 shares in the company, valued at $50,325.90. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 127,668 shares of company stock worth $286,211. 11.25% of the stock is owned by insiders.

Institutional Trading of Cabaletta Bio

A number of hedge funds have recently modified their holdings of CABA. Bain Capital Life Sciences Investors LLC grew its holdings in Cabaletta Bio by 250.5% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 9,677,125 shares of the company’s stock worth $14,709,000 after acquiring an additional 6,916,237 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Cabaletta Bio by 142.9% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock worth $13,421,000 after purchasing an additional 5,195,285 shares in the last quarter. Millennium Management LLC boosted its position in Cabaletta Bio by 298.5% in the 4th quarter. Millennium Management LLC now owns 2,736,912 shares of the company’s stock worth $5,994,000 after purchasing an additional 2,050,099 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Cabaletta Bio by 17.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company’s stock worth $21,590,000 after purchasing an additional 1,495,768 shares during the period. Finally, Woodline Partners LP increased its stake in shares of Cabaletta Bio by 75.2% in the 3rd quarter. Woodline Partners LP now owns 2,135,348 shares of the company’s stock valued at $4,997,000 after purchasing an additional 916,884 shares in the last quarter.

Key Headlines Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised multiple quarterly and annual EPS forecasts (example: FY2026 to ($1.51) from ($1.89); FY2027 to ($1.48) from ($1.97); FY2028 to ($1.41) from ($1.86); FY2029 to ($0.64) from ($0.92)), signaling improving expectations for Cabaletta’s financial trajectory. MarketBeat: CABA analyst updates
• Positive Sentiment: HC Wainwright also updated quarterly 2026 estimates (Q1–Q4 2026 moved roughly from ~$0.47 loss per share to ~$0.36–$0.40 loss per share), which could reduce near‑term downside risk if company performance follows these assumptions. MarketBeat: CABA analyst updates
• Neutral Sentiment: Despite upgrades, consensus full‑year estimates remain negative (MarketBeat consensus listed at about ($2.34) per share), and meaningful profitability is projected only in the long term (FY2030). The stock remains a speculative, binary biotech investment dependent on clinical and commercial execution. MarketBeat: CABA consensus data

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.